Oral Biologics Market to reach Size of US$ 8,087.5 Mn during forecast period 2019-2026 | Market Insights: Growth Factors, Market Drivers, Segmentations, Top Key Players, and in-Depth Research Report
Global Oral Biologics Market Insights
A biologic drug is a product that is produced from living organisms or contains components of living organism. These living organisms could be from animal, human or microorganism by using biotechnology. Biologic therapeutics has proven to be a highly effective treatment for various chronic ailments, such as diabetes, plaque psoriasis, arthritis, Crohn’s disease, and ulcerative colitis.
Currently, majority of the biological products are administered through parental route of administration. However, oral biologics represent a novel category of drugs, which is gaining traction in the last few decades. Moreover, major players in the market are working for the development of oral biologics and launch them in market, however, major concern regarding oral biologics is to protect the protein from degradation and digestion in the gastrointestinal tract.
Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/989
Robust research and development activities for development of novel oral biologics is expected fuel the market growth
Major companies in the market are involved in various strategies such as research and development, which is expected to drive growth of the global oral biologics market during the forecast period. For instance, in February 2019, researchers at Massachusetts Institute of Technology (MIT) developed a drug capsule with the potential to deliver an oral insulin named SOMA capsule, thereby replacing (or eliminating) the need to administer insulin via injections multiple times a day for patients with type 1 diabetes. The researchers stated that the drugs is currently under preclinical studies and is expected to enter clinical trials by 2022.
The research was funded by Novo Nordisk, the National Institutes of Health, a National Science Foundation Graduate Research Fellowship, Brigham and Women’s Hospital, a Viking Olaf Bjork Research Scholarship, and the MIT Undergraduate Research Opportunities Program.
Hence, such robust research and development activities by key players is expected to create a conducive environment and support global oral biologics market growth over the forecast period.
The global oral biologics market size was valued at US$ 834.3 Mn in 2018, and is expected to witness a CAGR of 32.8% during the forecast period (2018 – 2026).
Get Discount For First Time Buyers
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/989
Figure 1. Global Oral Biologics Market Value (US$ Mn) Analysis and Forecast, and Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2018)
Increasing partnerships and collaborations by market players is expected to create conducive environment for global oral biologics market growth
Key companies in the market are involved in strategic partnerships and collaborations, in order to gain edge in the market, which in turn, is expected to drive the market growth in the near future.
For instance, in 2016, Rani Therapeutics collaborated with Medimmune, a research and development subsidiary of AstraZeneca, to evaluate Rani Therapeutics’ novel oral drug delivering platform. This collaboration is expected to facilitate feasibility studies of drugs and test biologic molecules in the area of metabolic disease, to evaluate oral delivery of molecules. The objective of this collaboration is to deliver biologics orally, in order to increase compliance and improve patients’ lives globally.
Figure 2. Global Oral Biologics Market Share (%) Analysis, By Region, 2026
Source: Coherent Market Insights Analysis (2018)
North America is expected to hold dominant position in the market, owing to presence of major players and frequent research by them
Among regions, North America is expected to hold dominant position in the global oral biologics market during the forecast period. The U.S. is expected to be most lucrative market for oral biologics in North America, as it is the biggest pharmaceutical market with high presence of major players. Furthermore, high healthcare expenditure, healthcare awareness, and high adoption rate of novel drugs make the U.S. most prominent market for oral biologics.
Key players in the market are focusing on gaining the U.S. Food and Drug Administration (FDA) approval for their oral biologics and launch them in the market. For instance, in March 2019, Novo Nordisk A/S submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for oral semaglutide, the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in a pill.
Approval and launch of novel oral biologics in the U.S. is expected to significantly drive the North America oral biologics market growth over the forecast period.
Global Oral Biologics Market Opportunity
According to Labiotech.eu, 2018, around half of the top 100 drug sales will be biologics by 2022. Moreover, around 2,700 biologics are currently in development, which means they can create a conducive biologics market post approval. However, the biological drugs are administered parentally, which can result in high treatment costs and lower adherence rates.
According to the research conducted by Rani Therapeutics in 2018, around 62% patients and 86% physicians reported that patients either skip their injection or consistently fail to inject the drug as prescribed. The research further stated that around 70% rheumatologists and 92% gastroenterologists believe that availability of pills would significantly increase patient compliance rates.
Thus, the availability of biologics in the form of oral pills is expected to increase compliance rate and patient comfort, which can significantly improve the patients’ health by changing the course of the disease and preventing further complications. Moreover, oral biologics could also lower medication costs and improve access while improving the health of millions with chronic diseases globally.
The U.S. Food and Drug Administration (FDA) issues guidelines and regulates biologics including: vaccines, blood and blood products, cellular and gene therapy products tissue and tissue products, and allergenics.
The Center for Biologics Evaluation and Research (CBER) is a part of the U.S. FDA that regulates biological products for human use, under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act.
CBER ensures that biological products are safe and effective and are readily available. CBER also promotes the safe and appropriate use of biological products.
CBER supports manufacturers to use appropriate standards in the development of medical products. The use of appropriate standards can facilitate product development and provide a more efficient evaluation of regulatory submissions, including investigational new drug applications (INDs), biologics license applications (BLAs), new drug applications (NDAs), investigational device exemptions (IDEs), premarket approval applications, and premarket notifications, supplements, and amendments.
Key players operating in the global oral biologics market include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Inc., Enteris BioPharma, Inc., Chiasma, Inc., and Allena Pharmaceuticals, Inc.About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire